Ipsogen appoints VP of business on eve of US expansion
This article was originally published in Clinica
Susan Hertzberg has been appointed vice-president of corporate business at Ipsogen (Marseille, France) and president of its US subsidiary based in New Haven, Connecticut. The firm specialises in developing molecular diagnostic assays for breast cancer and leukaemia. She joins the firm as it plans to expand its business in both the North American market and globally. Ms Hertzberg joins from Abbott Diagnostics, where she was general manager of global accounts. And she spent much of her career at Quest Diagnostics, including as vice-president of purchasing and materials management, and as vice-president of marketing. Her commercial expertise and knowledge of the IVD and laboratory sectors will be a “great advantage”, said the firm’s CEO Vincent Fert.
You may also be interested in...
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.